Vasoactive intestinal peptide receptor expression on human lymphoblasts

M. Sue O’Dorisio, Barry T. Shannon, Arlynne F. Mulne, David Zwick, Neil J. Grossman, Frederick B. Ruymann

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study was designed to determine which (if any) subtypes of leukemic blasts express a functional receptor for vasoactive intestinal peptide (VIP). Blasts harvested from bone marrow of 38 newly diagnosed patients were classified as acute lymphocytic leukemia (CALLA + pre-B-cell leukemia, CALLA-, pre-B-cell leukemia, T-cell leukemia) or acute myeloid leukemia based on cytochemical and histochemical markers. Of the 32 patients with lymphocytic leukemia, 22 expressed the VIP receptor as evidenced by VIP-mediated activation of adenylate cyclase in cell homogenates. Binding of 125I-VIP to ALL cells correlated with the ability of VIP to activate adenylate cyclase. The VIP receptor was not identified in myeloid blasts from any of six patients. Further correlation of 125I-VIP binding and VIP-mediated stimulation of adenylate cyclase was demonstrated in transformed cell lines: a pre-B-cell line (Nalm 6) and a T-cell line (Molt 4b) exhibited high-affinity binding of 125I-VIP and VIP-mediated activation of adenylate cyclase, whereas neither the histiocytic line (U937) nor the myelocytic line (HL60) appeared to express the VIP receptor. These observations suggest a role for VIP in the proliferation or differentiation of human T and B lymphocytes.

Original languageEnglish (US)
Pages (from-to)144-150
Number of pages7
JournalJournal of Pediatric Hematology/Oncology
Volume14
Issue number2
StatePublished - Jan 1 1992

Fingerprint

Vasoactive Intestinal Peptide Receptors
Vasoactive Intestinal Peptide
Adenylyl Cyclases
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
T-Lymphocytes
T-Cell Leukemia
Lymphoid Leukemia
Cell Line
Transformed Cell Line
B-Lymphoid Precursor Cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
B-Lymphocytes
Bone Marrow

Keywords

  • Acute lymphocytic leukemia
  • Acute myeloid leukemia
  • CALLA
  • Lymphoblasts
  • Vasoactive intestinal peptide

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

O’Dorisio, M. S., Shannon, B. T., Mulne, A. F., Zwick, D., Grossman, N. J., & Ruymann, F. B. (1992). Vasoactive intestinal peptide receptor expression on human lymphoblasts. Journal of Pediatric Hematology/Oncology, 14(2), 144-150.

Vasoactive intestinal peptide receptor expression on human lymphoblasts. / O’Dorisio, M. Sue; Shannon, Barry T.; Mulne, Arlynne F.; Zwick, David; Grossman, Neil J.; Ruymann, Frederick B.

In: Journal of Pediatric Hematology/Oncology, Vol. 14, No. 2, 01.01.1992, p. 144-150.

Research output: Contribution to journalArticle

O’Dorisio, MS, Shannon, BT, Mulne, AF, Zwick, D, Grossman, NJ & Ruymann, FB 1992, 'Vasoactive intestinal peptide receptor expression on human lymphoblasts', Journal of Pediatric Hematology/Oncology, vol. 14, no. 2, pp. 144-150.
O’Dorisio MS, Shannon BT, Mulne AF, Zwick D, Grossman NJ, Ruymann FB. Vasoactive intestinal peptide receptor expression on human lymphoblasts. Journal of Pediatric Hematology/Oncology. 1992 Jan 1;14(2):144-150.
O’Dorisio, M. Sue ; Shannon, Barry T. ; Mulne, Arlynne F. ; Zwick, David ; Grossman, Neil J. ; Ruymann, Frederick B. / Vasoactive intestinal peptide receptor expression on human lymphoblasts. In: Journal of Pediatric Hematology/Oncology. 1992 ; Vol. 14, No. 2. pp. 144-150.
@article{4653303d376e44e5b702d5754b40471c,
title = "Vasoactive intestinal peptide receptor expression on human lymphoblasts",
abstract = "This study was designed to determine which (if any) subtypes of leukemic blasts express a functional receptor for vasoactive intestinal peptide (VIP). Blasts harvested from bone marrow of 38 newly diagnosed patients were classified as acute lymphocytic leukemia (CALLA + pre-B-cell leukemia, CALLA-, pre-B-cell leukemia, T-cell leukemia) or acute myeloid leukemia based on cytochemical and histochemical markers. Of the 32 patients with lymphocytic leukemia, 22 expressed the VIP receptor as evidenced by VIP-mediated activation of adenylate cyclase in cell homogenates. Binding of 125I-VIP to ALL cells correlated with the ability of VIP to activate adenylate cyclase. The VIP receptor was not identified in myeloid blasts from any of six patients. Further correlation of 125I-VIP binding and VIP-mediated stimulation of adenylate cyclase was demonstrated in transformed cell lines: a pre-B-cell line (Nalm 6) and a T-cell line (Molt 4b) exhibited high-affinity binding of 125I-VIP and VIP-mediated activation of adenylate cyclase, whereas neither the histiocytic line (U937) nor the myelocytic line (HL60) appeared to express the VIP receptor. These observations suggest a role for VIP in the proliferation or differentiation of human T and B lymphocytes.",
keywords = "Acute lymphocytic leukemia, Acute myeloid leukemia, CALLA, Lymphoblasts, Vasoactive intestinal peptide",
author = "O’Dorisio, {M. Sue} and Shannon, {Barry T.} and Mulne, {Arlynne F.} and David Zwick and Grossman, {Neil J.} and Ruymann, {Frederick B.}",
year = "1992",
month = "1",
day = "1",
language = "English (US)",
volume = "14",
pages = "144--150",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Vasoactive intestinal peptide receptor expression on human lymphoblasts

AU - O’Dorisio, M. Sue

AU - Shannon, Barry T.

AU - Mulne, Arlynne F.

AU - Zwick, David

AU - Grossman, Neil J.

AU - Ruymann, Frederick B.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - This study was designed to determine which (if any) subtypes of leukemic blasts express a functional receptor for vasoactive intestinal peptide (VIP). Blasts harvested from bone marrow of 38 newly diagnosed patients were classified as acute lymphocytic leukemia (CALLA + pre-B-cell leukemia, CALLA-, pre-B-cell leukemia, T-cell leukemia) or acute myeloid leukemia based on cytochemical and histochemical markers. Of the 32 patients with lymphocytic leukemia, 22 expressed the VIP receptor as evidenced by VIP-mediated activation of adenylate cyclase in cell homogenates. Binding of 125I-VIP to ALL cells correlated with the ability of VIP to activate adenylate cyclase. The VIP receptor was not identified in myeloid blasts from any of six patients. Further correlation of 125I-VIP binding and VIP-mediated stimulation of adenylate cyclase was demonstrated in transformed cell lines: a pre-B-cell line (Nalm 6) and a T-cell line (Molt 4b) exhibited high-affinity binding of 125I-VIP and VIP-mediated activation of adenylate cyclase, whereas neither the histiocytic line (U937) nor the myelocytic line (HL60) appeared to express the VIP receptor. These observations suggest a role for VIP in the proliferation or differentiation of human T and B lymphocytes.

AB - This study was designed to determine which (if any) subtypes of leukemic blasts express a functional receptor for vasoactive intestinal peptide (VIP). Blasts harvested from bone marrow of 38 newly diagnosed patients were classified as acute lymphocytic leukemia (CALLA + pre-B-cell leukemia, CALLA-, pre-B-cell leukemia, T-cell leukemia) or acute myeloid leukemia based on cytochemical and histochemical markers. Of the 32 patients with lymphocytic leukemia, 22 expressed the VIP receptor as evidenced by VIP-mediated activation of adenylate cyclase in cell homogenates. Binding of 125I-VIP to ALL cells correlated with the ability of VIP to activate adenylate cyclase. The VIP receptor was not identified in myeloid blasts from any of six patients. Further correlation of 125I-VIP binding and VIP-mediated stimulation of adenylate cyclase was demonstrated in transformed cell lines: a pre-B-cell line (Nalm 6) and a T-cell line (Molt 4b) exhibited high-affinity binding of 125I-VIP and VIP-mediated activation of adenylate cyclase, whereas neither the histiocytic line (U937) nor the myelocytic line (HL60) appeared to express the VIP receptor. These observations suggest a role for VIP in the proliferation or differentiation of human T and B lymphocytes.

KW - Acute lymphocytic leukemia

KW - Acute myeloid leukemia

KW - CALLA

KW - Lymphoblasts

KW - Vasoactive intestinal peptide

UR - http://www.scopus.com/inward/record.url?scp=0026607627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026607627&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 144

EP - 150

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 2

ER -